The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models: Methods and results from the NCI chemoprevention drug development program
Abstract
In the NCI, Chemoprevention Branch drug development program, potential chemopreventive agents are evaluated for efficacy against chemical carcinogen-induced tumors in animal models. This paper summarizes the results of 144 agents in 352 tests using various animal efficacy models. Of these results, 146 were positive, representing 85 different agents. The target organs selected for the animals model are representative of high-incidence human cancers. The assays include inhibition of tumors induced by MNU in hamster trachea, DEN in hamster lung, AOM in rat colon (including inhibition of AOM-induced aberrant crypts), MAM in mouse colon, DMBA and MNU in rat mammary glands, DMBA promoted by TPA in mouse skin, and OH-BBN in mouse bladder. The agents tested may be classified into various pharmacological and chemical structural categories that are relevant to their chemopreventive potential. These categories include antiestrogens, antiinflammatories (e.g., NSAIDs), antioxidants, arachidonic acid metabolism inhibitors, GST and GSH enhancers, ODC inhibitors, protein kinase C inhibitors, retinoids and carotenoids, organosulfur compounds, calcium compounds, vitamin D3 and analogs, and phenolic compounds (e.g., flavonoids). The various categories of compounds have different spectra of efficacy in animal models. In hamster lung, GSH-enhancing agents and antioxidants appear to have high potential for inhibiting carcinogenesis. In the colon, NSAIDs and other antiinflammatory agents appear particularly promising. Likewise, NSAIDs are very active in mouse bladder. In rat mammary glands, retinoids and antiestrogens (as would be expected) are efficacious. Several of the chemicals evaluated also appear to be promising chemopreventive agents based on their activity in several of the animal models. Particularly, the ODC inhibitor DFMO was active in the colon, mammary glands, and bladder models, while the dithiolthione, oltipraz, was efficacious in all the models listed above (i.e., lung, colon, mammary glands, skin, and bladder).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanism and inhibition of cytochrome P-450 aromatase
Cole, P. A., & Robinson, C. H. (1990) · Journal of Medicinal Chemistry · doi:10.1021/jm00173a001 · Cited by 319
Modulation of growth, differentiation and carcinogenesis by dehydroepiandrosterone.
Gordon, G. B., Shantz, L. M., & Talalay, P. (1987) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(87)90023-9 · Cited by 159
Cited by
Progress in Cancer Chemoprevention: Development of Diet-Derived Chemopreventive Agents
Kelloff, G. J., Crowell, J. A., Steele, V. E., Lubet, R. A., Malone, W. A., Boone, C. W., Kopelovich, L., Hawk, E. T., Lieberman, R., Lawrence, J. A., et al. (2000) · The Journal of Nutrition · doi:10.1093/jn/130.2.467s · Cited by 441
Self-citationLv, X., Zhao, S., Ning, Z., Zeng, H., Shu, Y., Tao, O., Xiao, C., Lu, C., & Liu, Y. (2015) · Chemistry Central Journal · doi:10.1186/s13065-015-0145-9 · Cited by 360
Perspectives on Cancer Chemoprevention Research and Drug Development
(1999) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)61026-x · Cited by 317
Panax ginseng—a non-organ-specific cancer preventive?
Yun, T.-K. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(00)00196-0 · Cited by 276
Metadata
- Authors
- Steele, V. E., Moon, R. C., Lubet, R. A., Grubbs, C. J., Reddy, B. S., Wargovich, M., McCormick, D. L., Pereira, M. A., Crowell, J. A., Bagheri, D., Sigman, C. C., Boone, C. W., & Kelloff, G. J.
- Venue
- Journal of Cellular Biochemistry
- Publisher
- Wiley
- Published
- 1994
- Volume
- 56
- Issue
- S20
- Pages
- 32-54
- ISSN
- 0730-2312 (ISSN-L)
- 1097-4644
- OpenAlex
- W2018208300
- Cited by
- 170
- References
- 2
- FWCI
- 3.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.